Bristol-Myers Squibb has partnered with biotech accelerator BioMotiv. Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.
“This new partnership will allow us to leverage the extensive expertise of Bristol-Myers Squibb across multiple disease areas,” stated Ted Torphy, BioMotiv’s chief executive officer and chief scientific officer. “Combined with BioMotiv’s unique model and focus on accelerating breakthrough discoveries from leading academic institutions, we have the opportunity to make a real impact on the lives of patients.”
